Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial
Tolvaptan was superior to FR at raising pNa over 3 days. However, intervention was required to prevent overcorrection in some, with no benefit in secondary outcomes. This is the first prospectively validated protocol to detect and prevent tolvaptan-related overcorrection.
Authors
- Jeffrey D. Zajac (ORCID: https://orcid.org/0000-0003-3933-5708)
- Annabelle M Warren (ORCID: https://orcid.org/0000-0002-7287-6162)
- Mathis Grossmann (ORCID: https://orcid.org/0000-0001-8261-3457)
- Nicholas Russell (ORCID: https://orcid.org/0000-0001-5596-6601)
- Rudolf Hoermann (ORCID: https://orcid.org/0000-0002-1326-4270)
- Rose Lin
Institutions
- Alfred Health (AU)
- Austin Health (AU)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1210/clinem/dgaf428
- Citations
- 2
- Primary Topic
- Electrolyte and hormonal disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Endocrine Society of Australia
- National Health and Medical Research Council